Ambroxol C₁₃H₁₈Br₂N₂O

Therapeutic indications

Ambroxol is indicated for:

Mucolytic therapy

Population group: both men and women, only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Ambroxol is indicated for mucolytic therapy of productive cough associated with acute or chronic bronchopulmonary diseases.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Mucolytic therapy

Population group: both men and women, only children (1 year - 12 years old)

Ambroxol is indicated for mucolytic therapy of productive cough associated with acute or chronic bronchopulmonary diseases.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Ambroxol is contraindicated in the following cases:

Pregnancy

Pregnancy

Breast-feeding

Lactation

Antitussives or with drugs that have an atropic effect

at least one of
Other cough suppressants
Atropine

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2016: FLAVAMED HUSTENSAFT Oral solution
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈